Astec Lifesciences
879.50
-26.80(-2.96%)
Market Cap₹1,711.10 Cr
PE Ratio-
IndustryChemicals
Company Performance:
1D-2.96%
1M-6.79%
6M-11.39%
1Y-26.90%
5Y-11.69%
View Company Insightsright
Latest news about Astec Lifesciences
Godrej Agrovet Boosts Stake in Astec LifeSciences to 67.03% via Market Purchase and Rights Issue 1 day ago Yesterday
Godrej Agrovet Limited increased its shareholding in Astec LifeSciences Limited from 63.36% to 67.03% through open market purchases and participation in a rights issue. The acquisition, completed on July 29, 2025, involved 25,31,229 additional shares, bringing Godrej Agrovet's total holding to 1,49,35,245 shares. Astec LifeSciences' equity share capital expanded from Rs. 19.61 crore to Rs. 22.28 crore. Godrej Agrovet filed a disclosure under Regulation 29(2) of SEBI regulations on July 31, 2025.
Astec Lifesciences Reports Q1 Revenue Growth Despite Continued Losses 5 days ago
Astec Lifesciences Announces ₹249.35 Crore Rights Issue Jul 02, 2025
Astec LifeSciences Announces ₹249.35 Crore Rights Issue at ₹890 Per Share Jun 30, 2025
Astec Lifesciences Surges 7.5% on ₹250 Crore Rights Issue Approval Jun 24, 2025
More news about Astec Lifesciences
19Jun 25
Astec Lifesciences to Discuss Fundraising Proposal in Upcoming Board Meeting
Astec Lifesciences, an agrochemical sector company, has announced a Board of Directors meeting on June 24 to discuss a fundraising proposal. The specific details of the potential fundraising, including its nature and amount, have not been disclosed. This meeting could have significant implications for the company's financial structure and future growth strategies.
24Apr 25
Astec Lifesciences Reports Widened Losses in Q4 FY2025 Amid Revenue Decline
Astec Lifesciences reported a consolidated net loss of ₹161.00 crore for Q4 FY2025, compared to a ₹9.70 crore loss in Q4 FY2024. Revenue declined 22.3% to ₹1,195.27 crore. Full-year FY2025 results show revenue at ₹3,813.03 crore and net loss at ₹1,347.12 crore. The Enterprise Business saw volume growth but profitability challenges, while CDMO experienced significant volume drops. Despite current challenges, management expects gradual improvement in the coming year.
23Apr 25
Astec Lifesciences Reports Widened Losses in Q4 and FY 2024-25 Amid Revenue Decline
Astec Lifesciences, a leading agrochemical company, reported increased losses for Q4 and FY 2024-25. Q4 saw a net loss of ₹160.79 crore, up from ₹9.70 crore last year, with revenue falling 22.26% to ₹119.53 crore. For FY 2024-25, net loss grew to ₹1,347.12 crore from ₹468.91 crore, while annual revenue dropped 16.78% to ₹381.30 crore. The company's debt-to-equity ratio is 2.36. Performance was impacted by reduced sales, pricing pressures, increased finance costs, and higher depreciation expenses. Management is focusing on cost optimization, product portfolio expansion, and exploring new markets to address challenges.
Astec Lifesciences
879.50
-26.80
(-2.96%)
1 Year Returns:-26.90%
Industry Peers
PI Industries
4,190.20
(-1.43%)
UPL
665.15
(-5.49%)
Sumitomo Chemical
630.65
(-2.78%)
Bayer Crop Science
6,254.50
(-1.08%)
Sharda Cropchem
1,106.90
(-2.69%)
Dhanuka Agritech
1,645.60
(-13.85%)
Rallis
367.15
(-2.47%)
NACL Industries
307.85
(-4.78%)
Bharat Rasayan
10,682.00
(-3.46%)